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THE COST-EFFECTIVENESS OF SCREENING
PROGRAMS USING SINGLE AND MULTIPLE
BIRTH COHORT SIMULATIONS: A 
COMPARISON USING A MODEL OF CERVICAL
CANCER
Dewilde S1,Anderson R2
1MEDTAP International, London, United Kingdom; 2CHERE,
University of Technology, Sydney, Australia
OBJECTIVE: The conventional single cohort approach
considers the impact of a change in screening policy only
on those who are about to enter the screening age range.
The multiple cohort simulation models the effect of
screening on the whole age-range affected by any policy
change, and takes into account the actual age distribution
in the population. We examined the effect of a single 
and a multiple birth cohort simulation on the incremen-
tal cost-effectiveness estimates of a cervical screening
program, comparing a two-yearly with a three-yearly
screening policy. METHODS: We use a 20-state Markov
model of the natural progression of cervical cancer and
pre-cancerous lesions for unscreened women developed
by the Duke University and adapted to the Australian
health care system. This model was modiﬁed with the
help of lookup tables to allow running 11 cohorts start-
ing at 5-year intervals. In the multiple cohort model, costs
and effects of each birth cohort are aggregated into a
weighted average, according to the proportion of each age
group in the target female population. RESULTS: Costs
and effects are both 15% lower in the multiple cohort
simulation, which is an expected result given the higher
average age in that group. Compared with a single birth
cohort simulation, the incremental cost-effectiveness of a
shift from two-yearly to three-yearly screening was 30%
higher when using the multiple cohort simulation:
AU$61,031 versus AU$47,361 per life year. So a policy-
shift from two-yearly to three-yearly screening is less cost-
effective in the multiple cohort simulation. Using different
age structures of four countries had very little impact on
the cost-effectiveness ratios: AU$61,690 for the USA,
AU$62,398 for the UK and AU$62,795 for Japan. CON-
CLUSION: Future modelling-based evaluations of screen-
ing policies should take greater account of the time
horizon of the decision, and also the age-range of the pop-
ulation that is targeted.
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LIFE EXPECTANCY AND THE DISCOUNTING
OF HEALTH OUTCOMES
Stant A, Groen HJM, Post WJ,TenVergert E
University Hospital Groningen, Groningen, Groningen,
Netherlands
OBJECTIVES: The topic of discounting health outcomes
in economic evaluations has led to much debate in the
ﬁeld of health technology assessment. In practice, health
outcomes are mainly discounted by means of the contro-
versial discounted utility (DU) model. When adopting an
individual perspective, as recommended by new welfare
economic theory, the main reason for discounting health
is uncertainty of the individual about the future. This
uncertainty is directly related to future health and, ulti-
mately, the occurrence and timing of death. The purpose
of this study is to examine the relevance of explicitly
including life expectancy in models of discounting.
METHODS: Aspects and assumptions that are relevant
for life expectancy and discounting health: a) the future
is not fully uncertain and individuals are aware of their
life expectancy; b) trade-offs among beneﬁts occurring at
different points in time will result in choosing to receive
health beneﬁts before the moment with a high probabil-
ity of being dead; and c) when the life expectancy of a
(patient) population is known, it is possible to identify
(time) cut-off points for individuals at which the proba-
bility of being alive is high, or at which the probability
of being dead is high. These points in time distinctively
inﬂuence the level of discounting. RESULTS: The stan-
dard DU model, which is insensitive to variation in life
expectancy, was compared with an alternative model of
discounting that explicitly includes life expectancy. In 
the current example, focusing on patients with a life
expectancy of 10 years, the alternative model led to
higher present values of future health outcomes when the
time horizon was less than 8 years. CONCLUSIONS:
Explicitly including life expectancy in models of dis-
counting seems to address some of the controversy sur-
rounding the discounting of health outcomes. Empirical
studies are needed to further explore the inﬂuence of life
expectancy on individual time preferences.
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OBJECTIVES: Chronic obstructive pulmonary disease
(COPD) is a major cause of mortality and morbidity in
Europe. This study will review and criticise available
information about epidemiological ﬁgures, cost of care
and cost or cost-effectiveness of therapeutic interventions
for COPD published in European countries. METHODS:
Literature search via PUBMED, EMBASE and Cochrane
Society was systematically conducted (covering January
1990 to March 2003) using the search terms: COPD, res-
piratory disease, epidemiology, incidence, prevalence,
treatment, costs and cost analysis, cost-of-illness, cost-
effectiveness, pharmacoeconomics. RESULTS: Of 479
matching articles, which were found for the epidemiology
review, only 9 studies were considered. These were cross-
sectional, population-based epidemiological studies with
precise epidemiologic information about the country or
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region. Figures for COPD prevalence vary from 3%
among Finnish women to 57% of Italians older than 45
years. Epidemiological research indicates that COPD is
an underdiagnosed and undertreated disease. The litera-
ture search for health economic articles generated 181
matching articles of which 26 analyses considered 
European health economics. Cost-of-illness and cost-
effectiveness studies were mainly used as analytic strate-
gies. Cost-of-illness studies indicate that hospital care and
medication are the major cost drivers in the treatment of
COPD. Annual direct expenditures per patient in Europe
range from €530 in France to €3239 in Spain. In cost-
effectiveness analyses, no uniformity in deﬁnition of out-
comes exist. Disease severity was not always delineated,
and the length of time horizon examined varied from 4
months to 2.5 years. CONCLUSION: Improvement of
diagnostic techniques and enforcement of professionalism
in diagnostic procedures as well as a uniform deﬁnition
of COPD have to be accomplished in order to obtain reli-
able epidemiological data and to ensure the quality of
health economics studies. These data could be used to
carry out health economics studies according to each
country´s guidelines or to develop them where no respec-
tive guidelines exist.
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IDENTIFICATION OF UNIT COSTS IN
RHEUMATOID ARTHRITIS—RESEARCH
APPROACH AND RESULTS
Rosery H, Schwander B, Bergemann R
Institute for Medical Outcome Research, Loerrach, Germany
OBJECTIVE: To elaborate a useful level of detail accord-
ing to measurement and valuation of costs associated
with rheumatoid arthritis. METHODS: Unit costs—com-
prehended as multiplicative part of costs as product of
amount and price—have a substantial impact on health
economic evaluations. Performing an intensive Internet
research we assessed country-speciﬁc unit costs for the 10
cost domains doctor visit, medication, diagnostic proce-
dures, monitoring, hospitalization, rehabilitation, per-
sonal help, stoppage, traveling and other treatments. The
most differentiated cost domains were rheumatic med-
ications (65 cost items) and monitoring (25 cost items).
We reported the type of cost item, country, total costs of
one unit, name of data source, date of data, homepage
address, date of review, calculation assumption and cal-
culation method. The evaluation was performed for Aus-
tralia, Canada, France, Germany, and Great Britain. All
unit costs were given in national currency as well as US$
for comparative purpose. RESULTS: Signiﬁcant differ-
ences in values of unit costs were identiﬁed with the Inter-
net research. The country-speciﬁc values of comparative
unit costs differed a lot. England and Australia show high
differences of unit cost values per type of doctor visit. All
ﬁve countries have high variances within the different
diagnostic procedures, the kind of personal help and the
type of traveling. The most differentiated references for
the evaluation of medication costs were found in
Germany. CONCLUSION: In general the identiﬁcation
of unit costs therefore has to adapt the speciﬁc payment
systems of health care. It is non-permissible to transfer
country-speciﬁc results to other countries. Because the
amount of unit costs differs a lot, each health economic
study report has to explain the used calculation approach.
Otherwise the user is unable to prove the robustness of
data. Additionally the performance of sensitivity analysis
is aggravated.
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OBJECTIVES: The German Agency for Health Technol-
ogy Assessment (DAHTA) at the German Institute for
Medical Documentation and Information (DIMDI) com-
missions research projects for Health Technology Assess-
ment (HTA). The authors were engaged to develop
methodological guidelines for the conduction of rapid
health economic HTA and simultaneously to conduct a
rapid health economic HTA to assess the cost-effective-
ness of Quantitative Ultrasound (QUS) as a technique for
screening and diagnosing osteoporosis. This abstract
describes ﬁrst experiences of the feasibility of the devel-
oped methodological guidelines made by the assessment
of cost-effectiveness of QUS. METHODS: Methodologi-
cal recommendations for rapid health economic HTA
were given to the following structural elements: study
question, background information, perspective, decision
analysis, searching and evaluation of information, dis-
cussion, conclusion, quality assurance and dissemination.
Based on this recommendations we conducted the assess-
ment of the cost-effectiveness of QUS. A detailed descrip-
tion of the guidelines as well as of the results of the
assessment of cost-effectiveness of QUS are given else-
where. RESULTS: Even though the methodological
guidelines turned out to be a proper instrument for the
conduction of rapid health economic HTA, two crucial
points should be pointed out: 1) study question should be
formulated precisely. We restricted the original study
question commissioned by DAHTA regarding to the
study population, number of compared technologies and
clinical outcome parameters; 2) methodological recom-
mendations clearly support the conduction of decision
modeling. In the case of QUS strong limitations could be
found, mainly due to the missing of effectiveness data.
CONCLUSION: The conduction of a rapid health eco-
nomic HTA demands careful considerations. In coopera-
tion with the potential addressee the study question
should be focused. In some cases, especially in the case a
decision analysis is demanded rapid health economic
